Neuren Pharmaceuticals Ltd 2024 Annual Report with Sustainability Disclosures
Company: Neuren Pharmaceuticals Ltd
Sector: Manufacturing
Country: Australia
Year: 2024
Type: Annual Report with Sustainability Disclosures
Pages: 60
The report presents 2024 as a record income year, with A$213.2 million in revenue from contracts with customers and A$142.0 million profit after tax. It highlights positive Phase 2 results for NNZ-2591 in Pitt Hopkins and Angelman syndromes and preparation for a first Phase 3 program in Phelan-McDermid syndrome. The ESG section reports zero Scope 1 and 2 emissions for the home-based 19-person workforce and describes the Group's governance framework.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.